Targeted delivery of transferrin and TAT co-modified liposomes encapsulating both paclitaxel and doxorubicin for melanoma

Drug Delivery

Volumn 23, Issue 4, 2016, Pages 1171-1183

  Yuan, Mingqing ^a   Qiu, Yue ^a   Zhang, Li ^b   Gao, Huile ^a   He, Qin ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Cancer; cell penetrating peptide; chemotherapy; drug delivery system; dual targeting

Indexed keywords

CELL PENETRATING PEPTIDE; CELL PENETRATING PEPTIDE TAT; DOXORUBICIN; LIGAND; LIPOSOME; PACLITAXEL; TRANSFERRIN; UNCLASSIFIED DRUG; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ASSAY; CANCER COMBINATION CHEMOTHERAPY; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG POTENTIATION; ENCAPSULATION; FLUORESCENCE; GENE OVEREXPRESSION; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LIPOSOMAL DELIVERY; MALE; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; STAINING; TUMOR SPHEROID; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG SCREENING; HUMAN; METABOLISM; PROCEDURES; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CELL-PENETRATING PEPTIDES; DOXORUBICIN; DRUG DELIVERY SYSTEMS; HUMANS; LIGANDS; LIPOSOMES; MELANOMA; PACLITAXEL; PEPTIDES; TRANSFERRIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84975257282     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2015.1040527     Document Type: Article

References (51)

1. T.M.Allen, P.R.Cullis. (2004). Drug delivery systems: entering the mainstream. Science 303:1818–22
2. E.M.Bolotin, R.Cohen, L.K.Bar,. (1994). Ammonium sulfate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandoliposomes. J Liposome Res 4:455–79
3. L.Brodin, P.Low, O.Shupliakov. (2000). Sequential steps in clathrin-mediated synaptic vesicle endocytosis. Curr Opin Neurobiol 10:312–20
4. J.Carlsson, J.Yuhas. (1984). Liquid-overlay culture of cellular spheroids. Spheroids Cancer Res 1--23. DOI: http://dx.doi.org/10.1007/978-3-642-82340-4_1
5. A.M.Chen, M.Zhang, D.Wei,. (2009). Co-delivery of Doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 5:2673–7
6. W.Chen, F.Meng, R.Cheng, Z.Zhong. (2010). pH-Sensitive degradable polymersomes for triggered release of anticancer drugs: a comparative study with micelles. J Control Release 142:40–6
7. T.R.Daniels, T.Delgado, J.A.Rodriguez,. (2006). The transferrin receptor, part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 121:144–58
8. R.Eaveri, A.Ben-Yehudah, H.Lorberboum-Galski. (2004). Surface antigens/receptors for targeted cancer treatment: the GnRH receptor/binding site for targeted adenocarcinoma therapy. Curr Cancer Drug Targets 4:673–87
9. A.El-Sayed, S.Futaki, H.Harashima. (2009). Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment. AAPS J 11:13–22
10. A.Fittipaldi, M.Giacca. (2005). Transcellular protein transduction using the Tat protein of HIV-1. Adv Drug Deliv Rev 57:597–608
11. E.A.Forssen, D.M.Coulter, R.T.Proffitt. (1992). Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res 52:3255–61
12. H.Gao, Z.Yang, S.Cao,. (2014a). Tumor cells and neovasculature dual targeting delivery for glioblastoma treatment. Biomaterials 35:2374–82
13. H.Gao, Z.Yang, S.Zhang,. (2013). Glioma-homing peptide with a cell-penetrating effect for targeting delivery with enhanced glioma localization, penetration and suppression of glioma growth. J Control Release 172:921–8
14. H.L.Gao, Z.Yang, S.Zhang,. (2014b). Study and evaluation of mechanisms of dual targeting drug delivery system with tumor microenvironment assays compared with normal assays. Acta Biomater 10:858–67
15. S.Jaracz, J.Chen, L.V.Kuznetsova, I.Ojima. (2005). Recent advances in tumor-targeting anticancer drug conjugates. Bioorg Med Chem 13:5043–54
16. A.Joliot, A.Prochiantz. (2004). Transduction peptides: from technology to physiology. Nature Cell Biol 6:189–96
17. G.Kibria, H.Hatakeyama, H.Harashima. (2011a). A new peptide motif present in the protective antigen of anthrax toxin exerts its efficiency on the cellular uptake of liposomes and applications for a dual-ligand system. Int J Pharm 412:106–14
18. G.Kibria, H.Hatakeyama, N.Ohga,. (2011b). Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. J Control Release 153:141–8
19. R.Kuai, W.Yuan, W.Li,. (2011). Targeted delivery of cargoes into a murine solid tumor by a cell-penetrating peptide and cleavable poly(ethylene glycol) comodified liposomal delivery system via systemic administration. Mol Pharm 8:2151–61
20. A.L.Lee, Y.Wang, H.Y.Cheng,. (2009). The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles. Biomaterials 30:919–27
21. S.Lee, M.Baek, H.-Y.Kim,. (2002). Mechanism of doxorubicin-induced cell death and expression profile analysis. Biotechnol Lett 24:1147–51
22. X.Li, H.Zhou, L.Yang,. (2011). Enhancement of cell recognition in vitro by dual-ligand cancer targeting gold nanoparticles. Biomaterials 32:2540–5
23. Y.R.Liu, J.X.Fang, Y.J.Kim,. (2014). Codelivery of doxorubicin and paclitaxel by cross-linked multilamellar liposome enables synergistic antitumor activity. Mol Pharm 11:1651–61
24. H.Maeda, J.Wu, T.Sawa,. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65:271–84
25. N.Maeda, Y.Takeuchi, M.Takada,. (2004). Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome. J Control Release 100:41–52
26. Y.Malam, M.Loizidou, A.M.Seifalian. (2009). Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharm Sci 30:592–9
27. F.O.Nestle, S.Alijagic, M.Gilliet,. (1998). Vaccination of melanoma patients with peptide- or tumorly sate-pulsed dendritic cells. Nat Med 4:328–32
28. R.Pérez-Tomás. (2006). Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 13:1859–76
29. Z.M.Qian, H.Li, H.Sun, K.Ho. (2002). Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 54:561–87
30. Y.Qin, H.Chen, Q.Zhang,. (2011). Liposome formulated with TAT-modified cholesterol for improving brain delivery and therapeutic efficacy on brain glioma in animals. Int J Pharm 420:304–12
31. L.Salter-Cid, A.Brunmark, Y.Li,. (1999). Transferrin receptor is negatively modulated by the hemochromatosis protein HFE: implications for cellular iron homeostasis. Proc Natl Acad Sci 96:5434–9
32. J.M.Saul, A.V.Annapragada, R.V.Bellamkonda. (2006). A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. J Control Release 114:277–87
33. R.M.Schiffelers, G.A.Koning, T.L.M.Ten Hagen,. (2003). Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J Control Release 91:115–22
34. B.Schutte, R.Nuydens, H.Geerts, F.Ramaekers. (1998). Annexin V binding assay as a tool to measure apoptosis in differentiated neuronal cells. J Neurosci Methods 86:63–9
35. J.Senior, G.Gregoriadis. (1982). Stability of small unilamellar liposomes in serum and clearance from the circulation: the effect of the phospholipid and cholesterol components. Life Sci 30:2123–36
36. G.Sharma, A.Modgil, B.Layek,. (2013). Cell penetrating peptide tethered bi-ligand liposomes for delivery to brain in vivo: biodistribution and transfection. J Control Release 167:1–10
37. R.Shew, D.Deamer. (1985). A novel method for encapsulation of macromolecules in liposomes. Biochim Biophys Acta 816:1–8
38. S.M.Stephenson, P.S.Low, R.J.Lee. (2004). Folate receptor-mediated targeting of liposomal drugs to cancer cells. Methods Enzymol 387:33–50
39. R.Suzuki, T.Takizawa, Y.Kuwata,. (2008). Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome. Int J Pharm 346:143–50
40. K.Takara, H.Hatakeyama, G.Kibria,. (2012). Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy. J Control Release 162:225–32
41. K.Takara, H.Hatakeyama, N.Ohga,. (2010). Design of a dual-ligand system using a specific ligand and cell penetrating peptide, resulting in a synergistic effect on selectivity and cellular uptake. Int J Pharm 396:143–8
42. R.B.Tishler, C.R.Geard, E.J.Hall, P.B.Schiff. (1992). Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 52:3495–7
43. V.P.Torchilin. (2008). TAT peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv Drug Deliv Rev 60:548–58
44. Y.Wang, S.Ma, Z.Xie, H.Zhang. (2014). A synergistic combination therapy with paclitaxel and doxorubicin loaded micellar nanoparticles. Colloids Surf B: Biointerfaces 116:41–8
45. R.A.Warren, F.A.Green, C.A.Enns. (1997). Saturation of the endocytic pathway for the transferrin receptor does not affect the endocytosis of the epidermal growth factor receptor. J Biol Chem 272:2116–21
46. K.Watson, R.J.Edwards. (1999). HIV-1 trans-activating (Tat) protein: both a target and a tool in therapeutic approaches. Biochem Pharmacol 58:1521–8
47. P.Youn, Y.Chen, D.Y.Furgeson. (2014). A myristoylated cell-penetrating peptide bearing a transferrin receptor-targeting sequence for neuro-targeted siRNA delivery. Mol Pharmaceut 11:486–95
48. S.E.Young, S.R.Martinez, R.Essner. (2006). The role of surgery in treatment of stage IV melanoma. J Surg Oncol 94:344–51
49. L.Zhang, F.X.Gu, J.M.Chan,. (2008). Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 83:761–9
50. T.Zong, L.Mei, H.Gao,. (2014a). Synergistic dual-ligand doxorubicin liposomes improve targeting and therapeutic efficacy of brain glioma in animals. Mol Pharm 11:2346–57
51. T.Zong, L.Mei, H.Gao,. (2014b). Enhanced glioma targeting and penetration by dual-targeting liposome co-modified with T7 and TAT. J Pharm Sci 103:3891–901